Phase 2 Non-small Cell Lung Cancer (NSCLC) Clinical Trials
42 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 42 trials
Recruiting
Phase 1Phase 2
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 2
Pembrolizumab for Advanced NSCLC and PS 2-3
Non-small Cell Lung Cancer (NSCLC)
Icahn School of Medicine at Mount Sinai45 enrolled1 locationNCT05589818
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Non-small Cell Lung Cancer (NSCLC)Ovarian CancerEndometrial Cancer+4 more
Shenzhen Ionova Life Sciences Co., Ltd.178 enrolled1 locationNCT07610798
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 2
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Genmab240 enrolled22 locationsNCT07288177
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1Phase 2
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament171 enrolled16 locationsNCT06567015
Recruiting
Phase 2
Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial
Brain Metastases, AdultBrain Metastases From Non-small Cell Lung Cancer (NSCLC)
University of Vermont Medical Center45 enrolled1 locationNCT06974370
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled85 locationsNCT06172478
Recruiting
Phase 1Phase 2
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled21 locationsNCT05379985
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Pancreatic CancerGastric CancerNon-small Cell Lung Cancer (NSCLC)+2 more
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1Phase 2
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Colorectal, CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.534 enrolled53 locationsNCT06128551
Recruiting
Phase 2
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Integro Theranostics35 enrolled2 locationsNCT07276789
Recruiting
Phase 2
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Brain Metastases, AdultBrain Tumor - MetastaticBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+1 more
Ayal A. Aizer, MD60 enrolled1 locationNCT07132190
Recruiting
Phase 2
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Brain Metastases, AdultBrain Metastases From Non-small Cell Lung Cancer (NSCLC)Brain Metastases From Extra-cranial Solid Tumors+2 more
Ayal A. Aizer, MD150 enrolled1 locationNCT07130786
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 2
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494